Pulmonary Disease, Chronic Obstructive — 28-day Repeat Dose Study of GSK573719
Citation(s)
A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD